Leveraging another source of external innovation, Eli Lilly has partnered with start-up Anima Biotech to discover and develop translation inhibitors for several targets. In a deal potentially worth more than US$1B, Anima will use its Translation Control Therapeutics platform to discover lead candidates for these targets, at which point Lilly will continue clinical development and commercialisation of the candidates. Anima’s cloud-based platform represents a new approach to addressing “undruggable” proteins by selectively regulating protein translation and has already been validated in-house across multiple therapy areas including viral infections, oncology and neuroscience.